Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 2012
May 18, 2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
May 18, 2012
Oncol Rep 2012
Schraml Peter, Moch Holger, Schläppi Marc, Seifert Bettina, Michielin Olivier, Dummer Reinhard, Ochsenbein Adrian, Simcock Mathew, Mihic-Probst Daniela, von Teichman Adriana, von Moos Roger
more
